Similarly, in prostate cancer, serum levels of IL-6 were higher in patients with obesity/insulin resistance and clinically evident hormone-resistant prostate cancer, compared to those with hormone-dependent cancer [122]. Here, IL6 is linked to obesity due to melanocortin 4 receptor deficiency.